Veracyte to Present at 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Conference Participation: Veracyte will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, showcasing its latest advancements in cancer diagnostics, which is expected to attract significant attention from investors and the healthcare industry.
- Live Webcast: The company will provide a live audio webcast of its presentations on its website, facilitating participation from global investors and healthcare professionals, thereby enhancing transparency and improving brand image.
- Replay Availability: A replay of the webcast will be available for 30 days post-event, allowing stakeholders who cannot attend live to access key information, further broadening the reach of their communications.
- Company Vision: Veracyte is committed to transforming cancer care through its high-performing diagnostics platform, leveraging extensive genomic and clinical data, which underscores its strategic importance in the cancer diagnostics field.
VCYT
$42.88+Infinity%1D
Analyst Views on VCYT
Wall Street analysts forecast VCYT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCYT is 42.17 USD with a low forecast of 28.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 42.490
Low
28.00
Averages
42.17
High
48.00
Current: 42.490
Low
28.00
Averages
42.17
High
48.00
About VCYT
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
